Himalaya Nutravedics IPO is a SME issue open from 22–24 September. The company is raising ₹26 Cr at a price band of ₹100 to ₹106 per share. One lot is 1,200 shares.
₹0
Implied listing gain: ₹106 (0.00%)
1.64x
Times the issue was bid for
On the GMP figure: grey market premium is quoted by informal dealers. No exchange publishes it, no regulator oversees it, and it is not a forecast of the listing price. Issues quoting a strong premium have listed below their issue price. Weigh the financials and the risk factors in the RHP well above this number.
Our reading of the numbers below — growth rates, margins, pricing and demand are calculated from the company's own filed figures, not copied from anywhere.
Minimum retail investment
₹1,27,200
1200 shares at the upper band of ₹106
Retail limit
1 lot
the most that fits under the ₹2 lakh retail cap
Funds blocked after close
~5 days
from the closing date to listing
Fresh issue share
96.2%
₹25 Cr of the ₹26 Cr issue
Revenue growth
+105.3%
31 Mar 2025 → 31 Mar 2026
Profit growth
+231.4%
PAT ₹2.23 Cr → ₹7.39 Cr
Net profit margin
17.1%
was 10.6% in 31 Mar 2025
Debt to equity
0.31
lower is safer
Return on equity
63.87%
ROE
Peer listing record
11 of 12 listed above issue price
median listing move +19.7%
Total subscription
1.64x
across all categories
Promoter holding
95.14% → 68.13%
diluted by 27 percentage points
Himalaya Nutravedics is an SME issue raising ₹26 Cr, offered in a band of ₹100–₹106 per share. At the upper end that is 10.6 times the ₹10 face value, so ₹96 of every share subscribed is share premium rather than capital. SME issues list on the BSE SME or NSE Emerge platform rather than the main board. They trade in fixed lots after listing, carry no retail-versus-HNI cut-off bidding, and are usually far less liquid, so exiting a position can take longer than on the main board.
A retail application for Himalaya Nutravedics needs one lot of 1200 shares, which works out to ₹1,27,200 at the upper band of ₹106. SME lots are deliberately sized above ₹1,00,000, so this is a far larger single commitment than a mainboard application and rules out most small investors. Retail applications are capped at ₹2,00,000, which here is 1 lot; bidding above that moves the application into the non-institutional category, and the large-HNI bucket begins at ₹10,00,000, or about 8 lots.
For Himalaya Nutravedics, bidding runs 22-24 Sep, allotment is finalised on 25 Sep 2026, the shares list on 29 Sep 2026. Applications that do not receive an allotment have their UPI mandate released around 1 day after the issue closes. Counting from the close of bidding, money stays blocked for roughly 5 days before listing decides what the holding is worth.
The issue is reserved 47.38% to qualified institutional buyers, 14.26% to non-institutional investors, 33.32% to retail. At 33.32%, the retail portion is on the narrower side, so retail allotment turns into a lottery quickly once the book fills. An oversubscribed retail portion is not allotted in proportion to the amount applied for: applications are reduced to single lots and drawn by lot, so several small applications from different PANs are more effective than one large one.
The issue splits into ₹25 Cr of fresh capital (96.2%) and ₹1 Cr as an offer for sale. The company keeps the fresh portion for the objects of the issue, while the rest is existing shareholders monetising their stake.
Revenue moved from ₹21 Cr in 31 Mar 2025 to ₹43.12 Cr in 31 Mar 2026 (+105.3%), while profit after tax went from ₹2.23 Cr to ₹7.39 Cr (+231.4%). Profit grew faster than revenue, which points to operating leverage or a better cost mix rather than growth bought purely through volume.
Recently listed companies in the same space trade at a median price-to-earnings ratio of about 20. Comparing that with the multiple implied by this issue's ₹100–₹106 band is a more useful test of pricing than looking at the grey market premium alone.
With the retail portion subscribed 2.56 times, roughly one in 3 single-lot applications can expect an allotment once the draw is made. Applying for more lots does not improve those odds in an oversubscribed retail book — every application is cut back to one lot before the lottery — so the practical lever is the number of distinct PANs applying, not the size of any one bid.
Kfin Technologies Ltd. is the registrar for this issue, which means the allotment status for Himalaya Nutravedics is published on their portal from 25 Sep 2026. A PAN, application number or demat client ID is enough to look it up; the credited shares also appear in the demat account itself a day or so before listing.
The figures above are worked out from the issue's own filed numbers and are for information only. They are not investment advice — read the RHP before you apply.
| IPO Date | 22–24 September |
| Face Value | ₹10 Per Share |
| Price Range | ₹100 to ₹106 |
| Issue Size | ₹26 Cr |
| Lot Size | 1,200 Shares |
| Allotment Date | 25 Sep 2026 |
| Listing Date | 29 Sep 2026 |
| Registrar | Kfin Technologies Ltd. |
| Category | Allocation |
|---|---|
| Retail Investors | 33.32% |
| QIB (Qualified Institutional Buyers) | 47.38% |
| HNI (High Net Worth Individuals) | 14.26% |
| Investor Category | Subscription (times) |
|---|---|
| Qualified Institutional | 1.00x |
| Non Institutional | 3.58x |
| Retail Individual | 2.56x |
| Total | 1.64x |
| Total Issue Size | 24,99,600 shares (agg. up to ₹26 Cr) |
| Reserved for Market Maker | 1,26,000 shares (agg. up to ₹1 Cr)Allwin Securities Ltd. |
| Fresh Issue (Ex Market Maker) | 23,73,600 shares (agg. up to ₹25 Cr) |
| Net Offered to Public | 23,73,600 shares (agg. up to ₹25 Cr) |
| Share Holding Pre Issue | 63,06,720 shares |
| Share Holding Post Issue | 88,06,320 shares |
| BSE Script Code | 544943 |
| ISIN | INE1OTR01013 |
| IPO Open | Tue, Sep 22, 2026 |
| IPO Close | Thu, Sep 24, 2026 |
| Allotment | Fri, Sep 25, 2026 |
| Refund | Mon, Sep 28, 2026 |
| Credit of Shares | Mon, Sep 28, 2026 |
| Listing | Tue, Sep 29, 2026 |
| Investor Category | Shares | % of Net Issue | % of Total Issue |
|---|---|---|---|
| QIB | 11,84,400 | 49.90% | 47.38% |
| − Anchor Investor | 7,10,400 | 28.42% | |
| − QIB (Ex. Anchor) | 4,74,000 | 18.96% | |
| NII (HNI) | 3,56,400 | 15.02% | 14.26% |
| − bNII > ₹10L | 2,37,600 | 9.51% | |
| − sNII < ₹10L | 1,18,800 | 4.75% | |
| Retail | 8,32,800 | 35.09% | 33.32% |
| Firm Reservations | |||
| Market Maker | 1,26,000 | 5.04% | |
| Total | 24,99,600 | 100.00% | 100.00% |
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual investors (IND) (Min) | 2 | 2400 | ₹2,54,400 |
| Individual investors (IND) (Max) | 2 | 2400 | ₹2,54,400 |
| S-HNI (Min) | 3 | 3600 | ₹3,81,600 |
| S-HNI (Max) | 7 | 8400 | ₹8,90,400 |
| B-HNI (Min) | 8 | 9600 | ₹10,17,600 |
| Bid Date | Mon, Sep 21, 2026 |
| Shares Offered | 7,10,400 |
| Anchor Portion (₹ Cr.) | 7.53 |
| Anchor lock-in period end date for 50% shares (30 Days) | Sat, Oct 24, 2026 |
| Anchor lock-in period end date for remaining shares (90 Days) | Wed, Dec 23, 2026 |
| Period Ended | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 24.42 | 10.82 | 6.09 |
| Total Income | 43.12 | 21.00 | 14.43 |
| Profit After Tax | 7.39 | 2.23 | 0.43 |
| EBITDA | 8.10 | 2.99 | 0.94 |
| NET Worth | 16.38 | 6.75 | 1.34 |
| Reserves and Surplus | 10.07 | 2.76 | 0.53 |
| Total Borrowing | 5.13 | 1.76 | 3.24 |
| Amount in ₹ Crore |
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Bio Medica Laboratories Ltd. | SME | ₹52.43 Cr | ₹139 | 13.03 | ₹115.80 | -16.69% | ₹166.00 |
| Goldline Pharmaceutical Ltd. | SME | ₹11.61 Cr | ₹43 | 10.47 | ₹56.77 | +32.02% | ₹32.00 |
| Speciality Medicines Ltd. | SME | ₹29.14 Cr | ₹124 | 9.27 | ₹125.90 | +1.53% | ₹164.90 |
| Accretion Nutraveda Ltd. | SME | ₹24.77 Cr | ₹129 | 26.27 | ₹191.20 | +48.22% | ₹269.80 |
| KRM Ayurveda Ltd. | SME | ₹77.49 Cr | ₹135 | 17.32 | ₹180.70 | +33.85% | ₹299.30 |
| Curis Lifesciences Ltd. | SME | ₹27.52 Cr | ₹128 | 12.44 | ₹141.00 | +10.16% | ₹230.10 |
| Aptus Pharma Ltd. | SME | ₹13.02 Cr | ₹70 | 11.29 | ₹84.84 | +21.20% | ₹353.90 |
| Symbiotec Pharmalab Ltd. | Mainboard | ₹1,757.00 Cr | ₹988 | 56.39 | ₹1,097.70 | +11.10% | ₹1,055.75 |
| Hexagon Nutrition Ltd. | Mainboard | ₹138.87 Cr | ₹45 | 22.69 | ₹53.19 | +18.20% | ₹64.35 |
| Sai Parenteral's Ltd. | Mainboard | ₹408.79 Cr | ₹392 | 72.19 | ₹405.70 | +3.49% | ₹509.95 |
| Corona Remedies Ltd. | Mainboard | ₹655.37 Cr | ₹1062 | 43.47 | ₹1,438.40 | +35.44% | ₹2,053.30 |
| Rubicon Research Ltd. | Mainboard | ₹1,377.50 Cr | ₹485 | 55.75 | ₹628.20 | +29.53% | ₹1,592.80 |
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Funding Working Capital Requirements | 13.75 |
| 2 | Business Development and Digital Marketing Activities | 7.50 |
| 3 | General Corporate Purposes | 3.17 |
| 4 | Issue Expenses | 2.08 |
| Total | 26.50 |
| KPI | Mar 31, 2026 |
|---|---|
| ROE | 63.87% |
| ROCE | 36.41% |
| Debt/Equity | 0.31 |
| RoNW | 45.12% |
| PAT Margin | 17.16% |
| EBITDA Margin | 18.82% |
| NAV | 26.70 |
| Price to Book Value | 3.97 |
| Valuation Metric | Pre IPO | Post IPO |
|---|---|---|
| EPS (₹) | 11.72 | 8.39 |
| P/E (x) | 9.04 | 12.63 |
| Market Cap at Offer Price | ₹66.85 Cr. | ₹93.35 Cr |
| Category | Pre IPO | Post IPO |
|---|---|---|
| Promoter and Promoter Group | 95.14% | 68.13% |
| Public | 4.86% | 31.87% |
| Total | 100% | 100% |
| Review By | Subscribe | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Brokers | 0 | 0 | 0 | 0 |
| Members | 0 | 0 | 0 | 0 |
| Category | Subscription (x) | Shares Offered | Shares bid for | Total Applications |
|---|---|---|---|---|
| QIB (Ex Anchor) | 1.00 | 4,74,000 | 4,74,000 | 0 |
| NII* | 3.58 | 3,56,400 | 12,74,400 | 0 |
| bNII (> ₹10L) | 3.84 | 2,37,600 | 9,13,200 | |
| sNII (< ₹10L) | 3.04 | 1,18,800 | 3,61,200 | |
| Individual Investor | 2.56 | 8,32,800 | 21,33,600 | 0 |
| Total | 2.33 | 16,63,200 | 38,82,000 | 1,039 |
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Fees and commissions payable to the BRLM and Syndicate Member (including underwriting commission, brokerage and selling and marketing commission | 1.46 |
| 2 | Commission/processing fee for SCSBs, Sponsor Bank(s) and Banker to the Issue and fee payable to the Sponsor Bank for Bids made by RIBs, Brokerage, selling commission and bidding charges for Member of the Syndicate, Registered Brokers, CRTAs and CDP and Market Maker Fees | 0.09 |
| 3 | Fee payable to Legal Counsel | 0.09 |
| 4 | Fees to regulators, including Stock Exchange i.e. Listing fees, Exchange’s filing fees, upload fees, Exchange’s processing fees, book building software fees, fees payable to the Registrar to the Issue, postages, depository charges and other regulatory expenses | 0.11 |
| 5 | Printing and distribution of stationery | 0.01 |
| 6 | Advertising and marketing expenses | 0.13 |
| 7 | Miscellaneous | 0.19 |
| Total | 2.08 |
Himalaya Nutravedics IPO is a SME issue open from 22–24 September. The company is raising ₹26 Cr at a price band of ₹100 to ₹106 per share. One lot is 1,200 shares.
The issue is open 22–24 September. Bids must be placed, and any UPI mandate approved, before the cut-off on the closing day.
The price band is ₹100 to ₹106 per equity share, against a face value of ₹10. Retail investors may bid at cut-off, meaning they accept the final discovered price within this band.
The minimum application is 1,200 shares, and bids must be in multiples of that lot.
The total issue size is ₹26 Cr.
The issue is reserved as retail 33.32%, QIB 47.38%, HNI 14.26%. If the retail portion is oversubscribed, allotment there is decided by a lottery on lot-sized applications rather than in proportion to the amount applied for.
Basis of allotment is expected to be finalised on 25 Sep 2026. You can check your status on the registrar's website (Kfin Technologies Ltd.) using your PAN.
Listing is expected on 29 Sep 2026, following the T+3 timeline that applies to Indian IPOs.
This information is for educational purposes only. Please conduct your own research and consult with financial advisors before making investment decisions. IPO investments carry market risks.
Or see the full upcoming IPO list, today's grey market premium, subscription figures and allotment status.

Option trading me majority retail traders loss karte hain. Is guide me janiye beginners ki common mistakes, risk management strategies aur kaise disciplined trading se losses avoid kiye ja sakte hain.

CMPDI IPO soon launch ho sakta hai jisme 7.14 crore shares OFS ke through offer kiye jayenge. Coal India shareholders ko special quota mil sakta hai. Yaha CMPDI IPO ki complete details aur investment strategy janiye.

US-Iran War ke baad se India mein crude oil $100 par, rupee record low ₹92 par, FPI ne ₹52,704 crore nikale, aur LPG sankat gahrata ja raha hai. Janiye is poori situation ka aapke investments par kya asar padega.